Enabling research and drug discovery
through better models of disease

Company Overview

Transposagen, Inc. is a privately-held biotechnology company founded in 2005 to commercialize early gene editing technology for the construction of rodent models of disease. Since then, Transposagen has significantly increased its scientific offerings to include a suite of gene editing technologies and services that address the research needs of both academic and drug discovery investigators.

The company is headquartered in Kentucky, located in a newly renovated historic building near downtown Lexington. Transposagen’s growing success and the unique piggyBac™ technology have yielded two spin-off companies, Poseida Therapeutics and Hera BioLabs, which focus on therapeutic development and toxicology testing, respectively.

Our Mission

Transposagen’s mission is to provide academic and drug discovery researchers with comprehensive gene editing products and services, empowering their efforts to discover the next generation of therapeutics. We accomplish this mission through internal innovation, in-licensing of cutting-edge technologies, and building lasting relationships with strategic partners.

Our Clients

Transposagen's customers and partners include many of the top pharmaceutical and biotechnology companies in the world, as well as numerous academic laboratories and government agencies. Our team of experts understands the needs of biomedical researchers, working one-on-one with customers to provide the best models and reagents to fit their exact requirements.

Our Technology

Learn how our proprietary piggyBac™ transposase technology and Footprint-Free™ gene editing systems are advancing research in a variety of scientific applications.

Learn More

Our People

Meet the people who make Transposagen a leader in genetically modified animal models, cell engineering services, and gene editing tools.

Learn More


Learn how we're teaming up with other trusted organizations to deliver comprehensive services and advanced products to researchers.

Learn More